Video
Dr. Haas on Adjuvant Sorafenib or Sunitinib for RCC
Author(s):
Naomi B. Haas, MD, associate professor, Abramson Cancer Center of the University of Pennsylvania, discusses the phase III ASSURE trial which looks at sorafenib or sunitinib for locally advanced renal cell carcinoma (RCC).
Naomi B. Haas, MD, associate professor, Abramson Cancer Center of the University of Pennsylvania, discusses the phase III ASSURE trial which looks at sorafenib or sunitinib for locally advanced renal cell carcinoma (RCC).
It was hypothesized that sorafenib or sunitinib could extend disease-free survival in the adjuvant setting. To test this, patients were classified based on risk (intermediate-high or very high), clear or non-clear histology, ECOG performance status, and surgery approach and treated for a year with either sunitinib, sorafenib, or placebo.
It was found that neither sorafenib nor sunitinib improved outcomes when administered after surgery to patients with RCC.
<<<
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
